Korinne Lee
Family · Surprise, AZNPI 1790306744
Payments from drug & device makers
Across 55 payments — averaging $61.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AstraZeneca$570
- AbbVie$197
- GSK$182
- Daiichi Sankyo Inc.$145
- Genentech USA, Inc.$143
- plus $857 from 16 others
What the payments were for
- Consulting fees$52515%
- Travel & lodging$90827%
- Food & beverage$1,94157%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,294 |
| AstraZeneca | 4 | $570 |
| AbbVie | 6 | $197 |
| GSK | 2 | $182 |
| Daiichi Sankyo Inc. | 2 | $145 |
| Genentech USA, Inc. | 1 | $143 |
| Pharmacosmos Therapeutics Inc. | 1 | $121 |
| Blueprint Medicines Corporation | 1 | $118 |
| Johnson & Johnson | 1 | $115 |
| Novo Nordisk | 6 | $111 |
| Gilead | 1 | $99 |
| Merck | 4 | $97 |
| Amgen | 2 | $29 |
| BETA Bionics, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Nevro Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$525
- INPEN SMART INSULIN DELIVERY SYSTEM$499
- InPen$307
- TECENTRIQ$143
- Monoferric$121
- AYVAKIT$118
- DARZALEX$115
How this compares
$3,388 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $24,211 |
| FarxigaDapagliflozin Propanediol | 17 | $23,851 |
| TrulicityDulaglutide | 12 | $17,739 |
| JanuviaSitagliptin Phosphate | 13 | $14,951 |
| Levothyroxine Sodium | 62 | $703 |
| Metformin Hcl ErMetformin Hcl | 29 | $319 |
| Glipizide ErGlipizide | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $111 | $24,21114 claims |
| AstraZenecaFarxiga | $570 | $23,85117 claims |
| Lilly USA, LLCTrulicity | $19 | $17,73912 claims |
| MerckJanuvia | $97 | $14,95113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.
Other family in Surprise
- Katherine RivasSurprise$34K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.